# Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

> **NCT05264493** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** NaxRedy ™
- **DRUG:** Naloxone Hydrochloride Injection, USP
- **DRUG:** Naloxone Hydrochloride Injection, USP

## Key facts

- **NCT ID:** NCT05264493
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-06
- **Primary completion:** 2021-01-08
- **Final completion:** 2021-01-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05264493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05264493, "Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05264493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*